(Reuters) – Moderna Inc raised its 2021 sales forecast for its COVID-19 vaccine by 4.3% to $19.2 billion on Thursday, reflecting demand from countries looking to return to normalcy through rapid inoculation.
Larger rival Pfizer Inc had said it expects $26 billion in sales of its COVID-19 vaccine this year.
(Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)
